Comparative in vitro activities of meropenem in combination with colistin, levofloxacin, or chloramphenicol against Achromobacter xylosoxidans strains isolated from patients with cystic fibrosis

Damar-Çelik D., Nørskov-Lauritsen N., Özbek-Çelik B.

Journal of Global Antimicrobial Resistance, vol.22, pp.713-717, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22
  • Publication Date: 2020
  • Doi Number: 10.1016/j.jgar.2020.06.001
  • Journal Name: Journal of Global Antimicrobial Resistance
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Page Numbers: pp.713-717
  • Keywords: Time-kill curve, Carbapenem, Nonfermentative, Bactericidal, Combination effect, ANTIMICROBIAL SUSCEPTIBILITY, PREVALENCE, STENOTROPHOMONAS, ANTIBIOTICS, RESISTANCE, INFECTION
  • Istanbul University Affiliated: Yes


Objectives: Achromobacter xylosoxidans is an emerging pathogen in cystic fibrosis (CF). Relatively little is known about its clinical impact and optimal management. In the present study, the in vitro bactericidal activities of meropenem, either alone or in combination with colistin, levofloxacin, or chloramphenicol, were assessed using A. xylosoxidans strains isolated from CF patients. The synergistic interactions of these combinations were also investigated.